ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL655
CHEMBL655
Compound Name MIDAZOLAM
ChEMBL Synonyms RO 21-3981/001 | BUCCOLAM | DORMICUM | MIDOZALAM HYDROCHLORIDE | MIDAZOLAM HYDROCHLORIDE | Rocam | RO 21-3981/003 | MIDAZOLAM | HYPNOVEL | Dormicum | MIDAZOLAM MALEATE | VERSED | Ro-21-3981-003
Max Phase 4 (Approved)
Trade Names VERSED | Dormicum | HYPNOVEL | DORMICUM | MIDAZOLAM HYDROCHLORIDE | MIDOZALAM HYDROCHLORIDE | Rocam | BUCCOLAM
Molecular Formula C18H13ClFN3

Additional synonyms for CHEMBL655 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Cc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4n12
Standard InChI InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14 ...
Download InChI
Standard InChI Key DDLIGBOFAVUZHB-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL655

Molecule Features

CHEMBL655 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
GABA-A receptor; anion channel positive allosteric modulator GABA-A receptor; anion channel ISBN

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
Dermatitis, AtopicD003876EFO:0000274atopic eczema1ClinicalTrials
Fluoride PoisoningD005458EFO:1001328fluoride poisoning3ClinicalTrials
Fractures, BoneD050723EFO:0003931bone fracture3ClinicalTrials
NauseaD009325EFO:0006911Chemotherapy-induced nausea and vomiting1ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:1001249non-alcoholic steatohepatitis1ClinicalTrials
Wounds and InjuriesD014947EFO:0000546injury3ClinicalTrials
AmnesiaD000647EFO:1001454amnesia1ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis1ClinicalTrials
Bipolar DisorderD001714EFO:0000289bipolar disorder2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm2ClinicalTrials
DementiaD003704HP:0000726dementia3ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy3ClinicalTrials
PainD010146EFO:0003843pain3ClinicalTrials
Skin DiseasesD012871EFO:0000701skin disease1ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease1ClinicalTrials
HypertensionD006973EFO:0000537hypertension3ClinicalTrials
HypotensionD007022EFO:0005251hypotension2ClinicalTrials
InfectionD007239EFO:0000544infection1ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma1ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm1ClinicalTrials
ClinicalTrials
Obsessive-Compulsive DisorderD009771EFO:0004242obsessive-compulsive disorder2ClinicalTrials
Osteoporosis, PostmenopausalD015663EFO:0003854postmenopausal osteoporosis1ClinicalTrials
Psychotic DisordersD011618EFO:0005411schizoaffective disorder1ClinicalTrials
Stress Disorders, Post-TraumaticD013313EFO:0001358post-traumatic stress disorder2ClinicalTrials
Subarachnoid HemorrhageD013345EFO:0000713subarachnoid hemorrhage2ClinicalTrials
AggressionD000374EFO:0003015aggressive behavior2ClinicalTrials
AtherosclerosisD050197EFO:0003914atherosclerosis1ClinicalTrials
Borderline Personality DisorderD001883HP:0012076Borderline personality disorder2ClinicalTrials
EndometriosisD004715EFO:0001065endometriosis1ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma1ClinicalTrials
SepsisD018805HP:0100806sepsis1ClinicalTrials
Shock, SepticD012772EFO:0006834septic shock1ClinicalTrials
Substance-Related DisordersD019966EFO:0003890drug dependence1ClinicalTrials
TonsillitisD0140692ClinicalTrials
AnemiaD000740EFO:0004272anemia1ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection1ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia1ClinicalTrials
NeoplasmsD009369EFO:0000311cancer1ClinicalTrials
SeizuresD012640HP:0001250Seizures2ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease1ClinicalTrials
AnxietyD001007EFO:0005230anxiety3ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma1ClinicalTrials
Communicable DiseasesD003141EFO:0005741infectious disease1ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus1ClinicalTrials
Influenza, HumanD007251EFO:0001669influenza infection1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma1ClinicalTrials
Renal InsufficiencyD0514371ClinicalTrials
TuberculosisD014376Orphanet:3389Tuberculosis1ClinicalTrials
ClinicalTrials
AspergillosisD001228EFO:0007157aspergillosis1ClinicalTrials
Cocaine-Related DisordersD019970EFO:0002610cocaine dependence1ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma1ClinicalTrials
Respiratory InsufficiencyD0121313ClinicalTrials
Adenomatous Polyposis ColiD011125EFO:0000662polyp2ClinicalTrials
Amyotrophic Lateral SclerosisD000690EFO:0000253amyotrophic lateral sclerosis1ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection1ClinicalTrials
Heart FailureD006333EFO:0003144heart failure1ClinicalTrials
Hepatitis B, ChronicD019694EFO:0004239chronic hepatitis B infection1ClinicalTrials
Hepatitis CD006526EFO:0003047hepatitis C infection1ClinicalTrials
Liver CirrhosisD008103EFO:0001422cirrhosis of liver3ClinicalTrials
Otitis MediaD010033EFO:0004992Otitis media2ClinicalTrials
Postoperative Nausea and VomitingD020250EFO:0004888post operative nausea and vomiting1ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis1ClinicalTrials
SchizophreniaD012559EFO:0000692schizophrenia3ClinicalTrials

Clinical Data

ClinicalTrials.gov MIDAZOLAM
The Cochrane Collaboration MIDAZOLAM

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL655. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1962 GABA receptor alpha-1 subunit Homo sapiens 1.000
CHEMBL250 Platelet activating factor receptor Homo sapiens 1.000
CHEMBL1889 Vasopressin V1a receptor Homo sapiens 0.999
CHEMBL4956 GABA receptor alpha-2 subunit Homo sapiens 0.979
CHEMBL4552 Peripheral-type benzodiazepine receptor Rattus norvegicus 0.895
CHEMBL1790 Vasopressin V2 receptor Homo sapiens 0.682



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL1962 GABA receptor alpha-1 subunit Homo sapiens 1.000
CHEMBL250 Platelet activating factor receptor Homo sapiens 1.000
CHEMBL1889 Vasopressin V1a receptor Homo sapiens 0.995
CHEMBL4956 GABA receptor alpha-2 subunit Homo sapiens 0.984
CHEMBL4552 Peripheral-type benzodiazepine receptor Rattus norvegicus 0.975
CHEMBL1790 Vasopressin V2 receptor Homo sapiens 0.845
CHEMBL3026 GABA receptor alpha-3 subunit Homo sapiens 0.809

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
325.8 325.0782 4.32 1 30.18 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
3 0 0 3 0 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 6.03 3.8 3.78 3 23 0.65

Structural Alerts

There are no structural alerts for CHEMBL655

Compound Cross References

ATC N - NERVOUS SYSTEM
N05 - PSYCHOLEPTICS
N05C - HYPNOTICS AND SEDATIVES
N05CD - Benzodiazepine derivatives
N05CD08 - midazolam

ChemSpider ChemSpider:DDLIGBOFAVUZHB-UHFFFAOYSA-N
DailyMed midazolam hydrochloride
PubChem SID: 50113067
Wikipedia Midazolam

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL655



ACToR 59467-70-8
BindingDB 21363
Brenda 12205 145058 145972
ChEBI 6931
ChemicalBook CB0418580
DrugBank DB00683
DrugCentral 1802
eMolecules 595333
EPA CompTox Dashboard DTXSID5023320
FDA SRS R60L0SM5BC
Guide to Pharmacology 3342
Human Metabolome Database HMDB0014821
IBM Patent System 65A79DEB3F8CF5DCAAEC8C53A0F28527
KEGG Ligand C07524
LINCS LSM-5200
Nikkaji J31.859K
PDBe 08J
PharmGKB PA450496
PubChem 4192
PubChem: Thomson Pharma 14850779
SureChEMBL SCHEMBL35061
ZINC ZINC000095626706

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/DDLIGBOFAVUZHB-UHFFFAOYSA-N spacer
spacer